Findings
========

The uveal melanoma (UM) is the most common primary intraocular tumor. Many studies reported genetic alterations in UM \[[@B1]\], but the causes are poorly understood. BAP1, a gene encoding a deubiquitinant enzyme, is mutated in several UM cases and in the malignant pleural mesothelioma (MPM) \[[@B2]\], a human tumour found be associated with the Simian Virus 40 (SV-40) infection \[[@B3],[@B4]\]. SV-40 oncogenic potential has been demonstrated in experimental animals \[[@B3],[@B4]\], while its mutagenic activities have been detected in different animal and human cell types \[[@B3],[@B4]\]. In human tumours, SV-40 was identified for the first time in a patient affected by a cutaneous melanoma \[[@B5]\], that shares the onset model with UM. Altogether these data were the background that prompted us to investigate the association between UM and SV-40 by analysing the prevalence of SV-40 antibodies in serum samples from UM affected patients. This study was carried out, as reported before, by an indirect Enzyme-Linked Immunosorbent Assay (ELISA) with SV-40 specific synthetic peptides derived from its viral proteins, without cross-reactivity with the closely related BKV and JCV which are obiquitous polyomaviruses in humans \[[@B6]\].

In this investigation, serum samples from UM affected patients (n = 48) and healthy subjects with ocular nevi (HSON; n = 71) and without ocular nevi (HS; n = 168), with the same median age (66 yrs), were analysed for presence of SV-40 antibodies. All patients and subjects were vaccinated against the poliomyelitis. The immunologic study was carried out by indirect ELISAs employing two specific mimotopes from SV-40 viral capsid proteins 1 and 2--3, named B and C peptides, respectively \[[@B6]\]. In our experiments, serum samples were considered SV-40 VP-positive upon reacting to both peptides B and C. Informed written consent was obtained from the patients and subjects. The study was approved by the County Ethical Committee, Ferrara, Italy.

The overall prevalence, by combining SV-40-positive sera for both VP1 B and VP2/3 C peptides, in UM patients was 33%, higher than that detected in HSON or HS, 17% and 15% respectively. The difference between UM patients and HSON or HS is statistically significant (p = 0.038 and p = 0.004, respectively). Serologic profiles of serum antibody reactivity to SV40 mimotopes are reported in Figure [1](#F1){ref-type="fig"}. The difference of OD=optical density mean value of sera from UM and two control groups, is not statistically significant (p \> 0.05).

![**Serologic profile.** Serologic profile of serum antibody reactivity to SV-40 mimotopes VP1 B **(panel A)** and VP2/3 C **(panel B)** and VPs B + C **(panel C)**. Immunologic data are from patients affected by UM and from healthy individuals (HS) with and without ocular nevi. Data are OD values at 405 nm of serum samples diluted 1:20, detected in indirect ELISA. In scatter dot plotting, each plot represents the dispersion of OD values to a mean level indicated by the line inside the scatter with standard error mean (SEM) for each group of subjects analyzed (Mean OD ± SEM).](1756-8722-7-38-1){#F1}

Our immunologic data indicate that a subset (1/3) of UM is associated with SV-40, a small DNA tumour virus detected as a contaminant in early anti-polio vaccines \[[@B3],[@B4],[@B7]\]. At present, SV-40 infection seems to spread in humans by different ways, including the urine and the faecal-oral route \[[@B3],[@B4],[@B7]\].

UM onset, like other human cancers, is due to specific gene mutations. Since SV-40 is oncogenic, clastogenic, mutagenic and a transforming viral agent \[[@B3],[@B7]\], may be a risk factor, together with other oncogenic agents such as the U.V. irradiation, in the UM onset/progression \[[@B8]\]. One may postulate that after infecting the host, SV-40 may exert its tumourigenic potential when the immune system is impaired. The high prevalence of SV-40 antibodies in sera from UM affected patients is not proof of cause/effect in inducing human tumours by SV-40. SV-40 DNA and expression of its oncogene, the large T antigen, should be analysed in UM specimens to confirm and extend the potential role of this oncogenic virus in UM onset/progression. We should also consider, as an alternative explanation, that another not yet discovered human Polyomavirus closely related to SV-40 may be responsible of our immunologic data. Our results from the laboratory bench could be transferred to the clinical application employing specific innovative therapies for SV40-positive UM patients.
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